Malignant Phyllodes Tumor of the Breast: Treatment and Prognosis

• DOI: 10.1111/tbj.12333
• Publication Date: 2014-09-17T05:24:13Z
• Authors: Jerzy Mituś; Marian Reinfuss; Jerzy W. Mituś; Jerzy Jakubowicz; Pawel Blecharz; Wojciech M. Wysocki; Piotr Skotnicki
• Keywords: Lumpectomy; Surgical margin; Breast-conserving surgery; Adjuvant radiotherapy

Surgery remains the mainstay of treatment in patients with malignant phyllodes tumor breast (MPTB); however, extent surgery (breast conserving [BCS] versus mastectomy) and role adjuvant radiotherapy have been controversial. We report a single institution's experience MPTB. discuss controversial therapeutic aspects this rare tumor. Seventy MPTB treated primarily were evaluated. The mean age was 50 years (21–76), size 6 cm. Thirty-four (48.6%) total mastectomy, 36 (51.4%) BCS (lumpectomy or wide local excision). Microscopic surgical margins free all cases. In 64 (91.4%) patients, ≥1 Remaining (8.6%) <1 cm subsequently performed. Among 70 58 (82.9%) had no evidence disease (NED) after 5 years. not significantly related to 5-year NED survival rates (82.4% who underwent mastectomy 83.3% only irradiation). (tumor-free margin cm) irradiation groups identical (83.3%). Our data support potential use Mastectomy is indicated if tumor-free cannot be obtained by BCS. Adjuvant may considered are